CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 27 enrolled
Drug / intervention
Revlimiddrug
Likely dose
Revlimid 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00360672
NCT00360672Phase 2Completed
CompareCT.gov

Phase II Study of Lenalidomide in Patients With Relapsed/Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplastic Syndrome Associated With Chromosome 5 Abnormalities

M.D. Anderson Cancer Center·interventional·Posted Aug 7, 2006·Updated Aug 14, 2013

In Brief

A Phase 2 clinical trial evaluating Revlimid for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Completed, enrolled 27 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to find out if Revlimid can help to control the disease in patients with relapsed/refractory acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS) with abnormalities in chromosome number 5. The safety of this treatment will also be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myelogenous Leukemia, Myelodysplastic Syndrome
CountriesUnited States
CollaboratorsCelgene Corporation

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 7, 2006
Enrollment StartJan 1, 2009
Primary CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 19.9 years ago

Interventions

Revlimiddrug

25 mg/day, orally for 21 days with 7 days rest (28 day cycle).